Intellia reports positive Phase 3 readout for CRISPR gene-editing therapy in hereditary angioedema

Intellia Therapeutics announced that its CRISPR-based therapy achieved a successful readout in a Phase 3 trial for hereditary angioedema, a rare condition marked by sudden, potentially dangerous swelling attacks.

The results were discussed by CEO John Leonard, who emphasized the significance of the data and the promise of a new treatment option for patients with limited existing therapies.

Leonard also outlined next steps, including plans for regulatory filing and broader development, highlighting the company’s commitment to advancing gene-editing medicines.